相关实验视频

Updated: Jul 3, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

通过调节Akt/FOXO3a通路,EMX2可以抑制清细胞细胞癌的进展

Xiaofeng Zhou^1,2,3,4, Sicheng Dong^1,2,3,4, Yuhao Zhou^1,2,3,4

¹Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Molecular carcinogenesis

|February 16, 2024

概括

空螺旋体Homeobox 2 (EMX2) 作为清细胞脏细胞癌 (ccRCC) 的瘤抑制剂. 较低的EMX2水平与预后不佳相关,其对Akt/FOXO3a通路的调节抑制了ccRCC的进展.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

空螺旋体Homeobox 2 (EMX2) 对于神经元发育至关重要,但其在清细胞细胞癌 (ccRCC) 中的作用基本上是未知的.
新出现的证据表明EMX2作为瘤抑制剂的功能,促使对其在ccRCC中的特定机制进行调查.

研究的目的:

阐明EMX2在调节ccRCC进展中的作用和潜在的分子机制.
确定在ccRCC中EMX2表达水平和患者预后之间的关系.

主要方法:

在ccRCC组织和细胞系中对EMX2表达的定量分析.
在体外测试 (细胞生长,迁移,入侵) 和体内研究 (裸体小鼠的瘤生长) 以评估EMX2功能.
对Akt/FOXO3a信号通路的研究,包括蛋白质酸化,表达水平和相互作用,使用诸如Western blotting和shRNA介导的淘汰等技术.

主要成果:

在ccRCC组织和细胞系中,EMX2表达显著下调,低表达与患者预后不佳相关.
过度表达EMX2抑制了ccRCC细胞的增殖,迁移和入侵在体外,并在体内抑制了瘤的生长.
EMX2通过减弱Akt酸化和增加FOXO3a表达来发挥其瘤抑制作用,从而抑制Akt/FOXO3a信号通路.

结论:

通过抑制细胞生长,迁移,入侵和瘤进展,EMX2作为ccRCC中的瘤抑制剂起作用.
在ccRCC中,Akt/FOXO3a信号通路是EMX2瘤抑制活性的关键调解者.
在ccRCC治疗中,EMX2是潜在的治疗点.

关键词:

这就是Akt/FOXO3a.在EMX2中使用EMX2.清细胞细胞癌是什么?

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...